Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | ATP4A | P20648 | 4/20 | 0.46 |
| ▸ | ATP4B | P51164 | 4/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 5/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | COMT | P21964 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19625399 | 0.87 | ATP4A (0.59) | PRMT6ATP4AATP4BGFERTSHR | |
| SCHEMBL19625374 | 0.79 | GFER (0.43) | PRMT6ATP4AATP4BGFERTSHR | |
| SCHEMBL12868318 | 0.76 | ATP4A (0.55) | PRMT6ATP4AATP4BTSHRRECQL | |
| SCHEMBL19627033 | 0.76 | GFER (0.41) | PRMT6ATP4AATP4BGFERTSHR | |
| SCHEMBL19625383 | 0.74 | SMN1; SMN2 (0.46) | PRMT6ATP4AATP4BGFERTSHR | |
| SCHEMBL19625323 | 0.74 | RAB9A (0.50) | ATP4AATP4BTSHR | |
| SCHEMBL12293307 | 0.74 | CYP19A1 (0.55) | ATP4AATP4BTSHRRECQL | |
| SCHEMBL19625319 | 0.74 | MAPT (0.62) | PRMT6TSHRRECQLL3MBTL1COMT | |
| SCHEMBL19625325 | 0.74 | KDM4E (0.62) | TSHRRECQLL3MBTL1COMT | |
| SCHEMBL799900 | 0.72 | ALDH1A1 (0.55) | ATP4AATP4BGFERLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | WNT1, WNT3A, CTNNB1 | PRMT6 1600/4885ATP4A 1734/4885ATP4B 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.